Vidane A S, Pinheiro A O, Casals J B, Passarelli D, Hage McFns, Bueno R S, Martins D S, Ambrósio C E
Department of Surgery, Faculty of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, SP, Brazil.
Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of São Paulo, Pirassununga, SP, Brazil.
Reprod Domest Anim. 2017 Apr;52 Suppl 2:316-326. doi: 10.1111/rda.12846. Epub 2016 Oct 23.
Chronic kidney disease (CKD) is a common clinical condition in domestic cats, characterized by tubulointerstitial, vascular and glomerular inflammation and severe fibrosis. Studies in rodent model of induced CKD have shown a decrease and stabilization of the clinical condition. In this study was evaluated the safety and effect of intrarenal and intravenous infusion of allogeneic mesenchymal stem cells (AMSCs) derived from feline amniotic membrane in cats with naturally occurring CKD. Cat AMSCs were harvested after mechanical and enzymatic digestion of amnion. A healthy cat received intrarenal injection of AMSCs guided by ultrasound in both kidneys (5 × 10 cells/kidney). Nine cats with CDK received repeated intravenous infusions of AMSCs (2 × 10 cells × 2 treatments). The clinical parameters of healthy cat did not change, but sedation and general anaesthesia was required. The number of interventions stressed the animal, and he developed transient haematuria after AMSC injection. Cats with CDK registered a significant improvement of renal function (decrease in serum creatinine and urine protein concentrations and increase in urine specific gravity). The kidney architecture and morphology did not change following the treatment. The feline AMSCs have a renoprotective effect and improve renal function in cats with naturally occurring CKD, stabilizing the clinical condition and disease progression. Thus, intravenous injection of AMSCs may be an important tool to provide welfare in cats with chronic kidney disease.
慢性肾脏病（CKD）是家猫常见的临床病症，其特征为肾小管间质、血管和肾小球炎症以及严重纤维化。对诱导性CKD啮齿动物模型的研究表明，临床病症有所减轻并趋于稳定。在本研究中，评估了将源自猫羊膜的同种异体间充质干细胞（AMSCs）经肾内和静脉输注给自然发生CKD的猫的安全性和效果。经机械和酶消化羊膜后收获猫AMSCs。一只健康猫在超声引导下接受双侧肾脏肾内注射AMSCs（5×10个细胞/肾）。9只患有CKD的猫接受了重复静脉输注AMSCs（2×10个细胞×2次治疗）。健康猫的临床参数未发生变化，但需要进行镇静和全身麻醉。干预次数使动物感到压力，且它在注射AMSCs后出现了短暂血尿。患有CKD的猫肾功能有显著改善（血清肌酐和尿蛋白浓度降低，尿比重增加）。治疗后肾脏结构和形态未发生变化。猫AMSCs对自然发生CKD的猫具有肾脏保护作用并能改善肾功能，稳定临床病症和疾病进展。因此，静脉注射AMSCs可能是为患有慢性肾脏病的猫提供福利的一项重要手段。
